Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Renalytix Plc is a precision diagnostics company focused on improving the early detection and management of kidney disease, particularly chronic kidney disease (CKD) and diabetic kidney disease. The company operates at the intersection of biotechnology, diagnostics, and artificial intelligence–enabled clinical decision support, combining biomarker science with advanced data analytics. Its core mission is to enable earlier, more accurate risk stratification to support timely intervention and improved patient outcomes.
The company’s primary product is KidneyIntelX, a laboratory-developed test that integrates blood-based biomarkers with electronic health record data and machine-learning algorithms to assess the risk of progressive kidney disease. Renalytix primarily serves healthcare providers, health systems, and payers, with a strong focus on patients with type 2 diabetes. The company was founded in 2018 and is headquartered in United Kingdom, with significant operational roots in academic research originating from Mount Sinai Health System in the United States.
Business Operations
Renalytix generates revenue primarily through the commercialization of KidneyIntelX, which is offered through centralized laboratory testing and reimbursed on a per-test basis where coverage applies. Operations are organized around a single reporting segment focused on precision diagnostics, encompassing research and development, clinical validation, regulatory activities, and commercial deployment.
The company conducts laboratory operations in the United States and leverages proprietary algorithms, validated biomarker panels, and licensed intellectual property. Renalytix maintains strategic collaborations with academic medical centers and healthcare systems to support clinical adoption, real-world evidence generation, and guideline inclusion. Its U.S. subsidiary, Renalytix AI, Inc., supports clinical, regulatory, and commercial activities in the American market.
Strategic Position & Investments
Renalytix’s strategy centers on expanding the clinical and economic value proposition of KidneyIntelX by securing broader reimbursement, increasing health system adoption, and generating outcomes-based evidence demonstrating cost savings and improved care pathways. The company has invested heavily in clinical studies and health economics research to support payer coverage decisions and guideline recommendations.
In addition to its lead product, Renalytix continues to explore pipeline extensions that apply its biomarker and AI platform to other kidney-related conditions and risk stratification use cases. The company has not disclosed a diversified portfolio of commercial products or major acquisitions; instead, it emphasizes internal development and licensing of biomarker technology from academic partners, including Mount Sinai.
Geographic Footprint
Renalytix operates primarily in the United States and the United Kingdom, with its corporate headquarters in the UK and its main laboratory and commercial operations based in the U.S. The United States represents the company’s most significant market due to the prevalence of diabetic kidney disease and the structure of diagnostic reimbursement.
The company also maintains a presence in Europe through research collaborations and regulatory engagement, though commercial activity outside the U.S. remains limited. Its geographic strategy prioritizes markets with established reimbursement frameworks for advanced diagnostics and large at-risk patient populations.
Leadership & Governance
Renalytix is led by an executive team with experience in diagnostics, life sciences, and healthcare commercialization. The leadership emphasizes evidence-based medicine, integration of diagnostics into clinical workflows, and alignment with payer and provider incentives to drive adoption.
Key executives include:
- James McCullough – Chief Executive Officer
- Peter Scott – Chief Financial Officer
- Stuart Fleming – Chief Medical Officer
- Hollis Slaven – Chief Commercial Officer
- Susan McLennan – Chief Legal Officer and Company Secretary
The board and management team maintain a governance approach aligned with public company standards in both the UK and U.S., with oversight focused on clinical validation, regulatory compliance, and long-term shareholder value creation.